JP2023516286A5 - - Google Patents
Info
- Publication number
- JP2023516286A5 JP2023516286A5 JP2022550781A JP2022550781A JP2023516286A5 JP 2023516286 A5 JP2023516286 A5 JP 2023516286A5 JP 2022550781 A JP2022550781 A JP 2022550781A JP 2022550781 A JP2022550781 A JP 2022550781A JP 2023516286 A5 JP2023516286 A5 JP 2023516286A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- domain containing
- identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/076937 | 2020-02-27 | ||
| CN2020076937 | 2020-02-27 | ||
| PCT/CN2021/078203 WO2021170100A1 (en) | 2020-02-27 | 2021-02-26 | Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023516286A JP2023516286A (ja) | 2023-04-19 |
| JP2023516286A5 true JP2023516286A5 (https=) | 2024-02-29 |
| JP7747645B2 JP7747645B2 (ja) | 2025-10-01 |
Family
ID=77490732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550781A Active JP7747645B2 (ja) | 2020-02-27 | 2021-02-26 | グリピカン－３（ｇｐｃ３）を標的化する抗体及びキメラ抗原受容体並びにその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230088461A1 (https=) |
| EP (1) | EP4110912A4 (https=) |
| JP (1) | JP7747645B2 (https=) |
| KR (1) | KR20220146456A (https=) |
| CN (1) | CN115151639A (https=) |
| AU (1) | AU2021225978A1 (https=) |
| BR (1) | BR112022016958A2 (https=) |
| CA (1) | CA3170023A1 (https=) |
| IL (1) | IL295774A (https=) |
| MX (1) | MX2022010360A (https=) |
| WO (1) | WO2021170100A1 (https=) |
| ZA (1) | ZA202209069B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230147619A (ko) * | 2021-02-26 | 2023-10-23 | 난징 레전드 바이오테크 씨오., 엘티디. | 외인적으로 도입된 사이토카인을 발현하는 조작된 면역이펙터 세포 |
| WO2024022509A1 (en) * | 2022-07-29 | 2024-02-01 | Nanjing Legend Biotech Co., Ltd. | Methods for promoting persistence of cell therapy |
| US20260027209A1 (en) * | 2022-07-29 | 2026-01-29 | Legend Biotech Ireland Limited | Claudin-6 binding moieties and uses thereof |
| CN117025541B (zh) * | 2023-08-15 | 2025-10-17 | 福建医科大学附属协和医院 | 一种靶向b7-h3并共表达细胞因子和趋化因子的car-t细胞及其用途 |
| WO2025159562A1 (ko) * | 2024-01-24 | 2025-07-31 | 국립암센터 | Gpc3에 특이적으로 결합하는 신규 항체 및 이의 용도 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050020806A (ko) * | 2002-05-23 | 2005-03-04 | 써니브룩 앤드 우먼스 칼리지 헬스 사이언시즈 센터 | 간세포암의 진단 |
| EP1684076B1 (en) * | 2003-10-29 | 2008-12-31 | Kumamoto Technology & Industry Foundation | Diagnostic method for malignant melanoma |
| SI1674111T1 (sl) * | 2004-07-09 | 2011-02-28 | Chugai Pharmaceutical Co Ltd | Protitelo proti glipikanu 3 |
| US7723043B2 (en) * | 2006-01-04 | 2010-05-25 | Picobella, Lp | Methods for screening for prostate cancer |
| SG11201407972RA (en) * | 2012-06-01 | 2015-01-29 | Us Health | High-affinity monoclonal antibodies to glypican-3 and use thereof |
| WO2015179658A2 (en) * | 2014-05-22 | 2015-11-26 | Genentech, Inc. | Anti-gpc3 antibodies and immunoconjugates |
| JP2017529851A (ja) * | 2014-09-26 | 2017-10-12 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 養子免疫療法のためのグリピカン−３特異的キメラ抗原レセプター |
| ES2818103T3 (es) * | 2015-01-16 | 2021-04-09 | Juno Therapeutics Inc | Anticuerpos y receptores de antígenos quiméricos específicos para ROR1 |
| JP2019532953A (ja) * | 2016-09-30 | 2019-11-14 | ノバルティス アーゲー | 増強された有効性を有する免疫エフェクター細胞治療 |
| MX2019008221A (es) * | 2017-01-10 | 2019-12-09 | Univ Yamaguchi | Anticuerpo anti-gpc3. |
| EP3615574A4 (en) * | 2017-04-26 | 2021-02-24 | Eureka Therapeutics, Inc. | SPECIFIC GLYPICAN 3 RECOGNIZING CONSTRUCTS AND THEIR USE |
| CN109385400A (zh) * | 2017-08-09 | 2019-02-26 | 科济生物医药（上海）有限公司 | 共表达pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| AR114112A1 (es) * | 2018-02-15 | 2020-07-22 | Seattle Genetics Inc | Anticuerpos de glipicano 3 y conjugados de los mismos |
| WO2020017479A1 (ja) * | 2018-07-17 | 2020-01-23 | ノイルイミューン・バイオテック株式会社 | 抗ｇｐｃ３一本鎖抗体を含むｃａｒ |
| CN110684120B (zh) * | 2019-10-12 | 2023-03-07 | 华夏源（上海）细胞基因工程股份有限公司 | 一种靶向gpc3的嵌合抗原受体及其应用 |
-
2021
- 2021-02-26 CA CA3170023A patent/CA3170023A1/en active Pending
- 2021-02-26 JP JP2022550781A patent/JP7747645B2/ja active Active
- 2021-02-26 CN CN202180016268.2A patent/CN115151639A/zh active Pending
- 2021-02-26 AU AU2021225978A patent/AU2021225978A1/en active Pending
- 2021-02-26 IL IL295774A patent/IL295774A/en unknown
- 2021-02-26 MX MX2022010360A patent/MX2022010360A/es unknown
- 2021-02-26 EP EP21759551.1A patent/EP4110912A4/en active Pending
- 2021-02-26 US US17/798,541 patent/US20230088461A1/en active Pending
- 2021-02-26 WO PCT/CN2021/078203 patent/WO2021170100A1/en not_active Ceased
- 2021-02-26 KR KR1020227028720A patent/KR20220146456A/ko active Pending
- 2021-02-26 BR BR112022016958A patent/BR112022016958A2/pt unknown
-
2022
- 2022-08-12 ZA ZA2022/09069A patent/ZA202209069B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023516286A5 (https=) | ||
| JP7724332B2 (ja) | クローディン１８．２結合部分およびその利用 | |
| JP2021087455A5 (https=) | ||
| KR102785140B1 (ko) | 신규 항-cd3엡실론 항체 | |
| CA3016287A1 (en) | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore | |
| FI4063397T3 (fi) | Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| CA3148329A1 (en) | Targeted immunotolerance with a pd-1 agonist | |
| RU2020120853A (ru) | Мультиспецифичные химерные рецепторы, содержащие домен nkg2d, и способы их применения | |
| JP2022542559A5 (https=) | ||
| RU2019126655A (ru) | Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль | |
| RS53072B (sr) | Antitela za humani receptor programirane smrti pd-1 | |
| KR20230024911A (ko) | 항-her2 항체 또는 이의 항원 결합 단편 및 이를 포함하는 키메라 항원 수용체 | |
| CN115279792B (zh) | 对bcma特异的抗体及嵌合抗原受体 | |
| KR20230143177A (ko) | 신규한 항-cd24 항체 | |
| CA3072394A1 (en) | Cd96-binding agents as immunomodulators | |
| EP3873936A1 (en) | Novel antagonistic anti tnfr2 antibody molecules | |
| CA3219642A1 (en) | Novel anti-cd276 antibodies and the uses thereof | |
| JP2025504795A (ja) | 抗体及びその用途 | |
| JP2024105603A (ja) | ＣＡＲライブラリおよびｓｃＦｖの製造方法 | |
| CA3199976A1 (en) | Polypeptide constructs selectively binding to cldn6 and cd3 | |
| WO2025148750A1 (zh) | 膜表达il-10及其用途 | |
| US20260055201A1 (en) | Bispecific antibody and use thereof | |
| AU2023365438A1 (en) | Use of anti-cldn4-anti-cd137 bispecific antibody combined with pd-1 signal inhibitor for cancer treatment | |
| AU2023411874A1 (en) | Antibody and use thereof | |
| CN115991786A (zh) | 用于靶向msln免疫细胞疗法的组合物 |